DALLAS, Feb. 11, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company International Stem Cell Corp. (OTCBB:ISCO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/ISCO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
International Stem Cell Corp. (ISCO) develops leading-edge stem cell technology called "parthenogenesis," a regenerative technology to reduce immune-rejection among many patients. The Company's parthenogenesis approach to combat medical pathologies utilizes unfertilized human eggs to yield "parthenogenetic" stem cells (hpSC), with the goal of providing "immune-matching" stem cell therapies through a network of stem cell banks worldwide.
In the report, the analyst notes:
"The Company's research has the potential to radically change patient treatment plans for a wide range of pathologies and diseases. Presently, adult stem cells have proven effective in the treatment of some diseases such as leukemia via bone marrow transplants. Stem cells are believed to be the future of medical treatment for patients afflicted with a wide range of pathologies and diseases.
"The Company's hpSC stem cell research centers focus upon the development of pluripotent cells, which have the capacity to become cell types not requiring manipulation of the genes. This type of research and development avoids ethical issues plaguing much of the industry. Instead, this unique process creates a homozygous product form which can then be immunologically matched to a broader range of patients."
To read the entire report visit: http://www.beaconequity.com/i/ISCO
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.